Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 20/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.59 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.57 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.57 |
| ▸ | TACR2 | P21452 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14241812 | 1.00 | SSTR3 (0.59) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL9909900 | 0.93 | SSTR3 (0.51) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL13244751 | 0.93 | SSTR3 (0.51) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL13244859 | 0.93 | SSTR3 (0.61) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL13458052 | 0.93 | SSTR3 (0.61) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL901932 | 0.85 | SSTR3 (0.80) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL23777544 | 0.83 | SSTR3 (0.81) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL9928505 | 0.83 | SSTR3 (0.64) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL13244746 | 0.83 | SSTR3 (0.81) | SSTR3KCNH2SSTR1SSTR5TACR2 | |
| SCHEMBL9928528 | 0.83 | SSTR3 (0.81) | SSTR3KCNH2SSTR1SSTR5TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2676961-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2676960-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2760855-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AS WELL AS THEIR USE IN TREATING TYPE-2 DIABETES | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2571876-B1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9422266-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422266-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9403790-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2538783-B1 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2016-05-19 | — | — | US | disclosed |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-06-23 | — | — | US | disclosed |
| WO-2011028455-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010108268-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| US-20100184799-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100184799-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| WO-2010043052-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010037225-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | SSTR3 590/4885KCNH2 2400/4885SSTR1 1728/4885 |
| US-20100184799-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | SSTR3 2/4885KCNH2 910/4885SSTR1 8/4885 |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | SSTR3 4505/4885KCNH2 4507/4885SSTR1 4158/4885 |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | SSTR3 590/4885KCNH2 2400/4885SSTR1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.